Journal article
Eosinophilic bioactivities in severe asthma.
- Carr TF University of Arizona, Tucson, Arizona USA.
- Berdnikovs S Northwestern University Feinberg School of Medicine, Chicago, Illinois USA.
- Simon HU Institute of Pharmacology, University of Bern, Bern, Switzerland.
- Bochner BS Northwestern University Feinberg School of Medicine, Chicago, Illinois USA.
- Rosenwasser LJ Children's Mercy Hospital, Kansas City, Missouri USA.
- 2016-07-08
Published in:
- The World Allergy Organization journal. - 2016
English
Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s40413-016-0112-5
- PMID 27386041
- Persistent URL
- https://sonar.ch/global/documents/123465
Statistics
Document views: 44
File downloads: